GR3021805T3 - Methods and compositions for the suppression of neu mediated transformation - Google Patents
Methods and compositions for the suppression of neu mediated transformationInfo
- Publication number
- GR3021805T3 GR3021805T3 GR960403196T GR960403196T GR3021805T3 GR 3021805 T3 GR3021805 T3 GR 3021805T3 GR 960403196 T GR960403196 T GR 960403196T GR 960403196 T GR960403196 T GR 960403196T GR 3021805 T3 GR3021805 T3 GR 3021805T3
- Authority
- GR
- Greece
- Prior art keywords
- gene
- neu
- suppression
- products
- expression
- Prior art date
Links
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000001629 suppression Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000009466 transformation Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 230000014509 gene expression Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108700020796 Oncogene Proteins 0.000 abstract 2
- 229920001817 Agar Polymers 0.000 abstract 1
- 208000005623 Carcinogenesis Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 101000856426 Mus musculus Cullin-7 Proteins 0.000 abstract 1
- 239000008272 agar Substances 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 230000036952 cancer formation Effects 0.000 abstract 1
- 231100000504 carcinogenesis Toxicity 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 108700020302 erbB-2 Genes Proteins 0.000 abstract 1
- 210000005002 female reproductive tract Anatomy 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
- 238000011277 treatment modality Methods 0.000 abstract 1
- 231100000588 tumorigenic Toxicity 0.000 abstract 1
- 230000000381 tumorigenic effect Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62146590A | 1990-12-04 | 1990-12-04 | |
| PCT/US1991/009100 WO1992010573A1 (en) | 1990-12-04 | 1991-12-04 | Methods and compositions for the suppression of neu mediated transformation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3021805T3 true GR3021805T3 (en) | 1997-02-28 |
Family
ID=24490270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR960403196T GR3021805T3 (en) | 1990-12-04 | 1996-11-28 | Methods and compositions for the suppression of neu mediated transformation |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5651964A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0560932B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JPH06504671A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE142261T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU651650B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2096723C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69121903T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0560932T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2093248T3 (cg-RX-API-DMAC7.html) |
| GR (1) | GR3021805T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1992010573A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641484A (en) * | 1990-12-04 | 1997-06-24 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| US5643567A (en) * | 1990-12-04 | 1997-07-01 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| US5516631A (en) * | 1992-10-13 | 1996-05-14 | La Jolla Cancer Research Foundation | Method of inhibiting replication of hyperproliferative cells |
| AU5962694A (en) * | 1992-12-31 | 1994-08-15 | Exemplar Corporation | Producing cells for transplantation to reduce host rejection and resulting cells |
| US5776743A (en) | 1994-09-06 | 1998-07-07 | La Jolla Cancer Research Foundation | Method of sensitizing tumor cells with adenovirus E1A |
| US6326356B1 (en) * | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5763415A (en) * | 1995-08-03 | 1998-06-09 | John Hopkins University School Of Medicine | Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer |
| US6861506B1 (en) | 1996-01-11 | 2005-03-01 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
| US6828431B1 (en) | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US7241876B2 (en) | 1996-01-11 | 2007-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6656480B2 (en) | 1996-01-11 | 2003-12-02 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
| CA2250222A1 (en) * | 1996-03-20 | 1997-09-25 | Mien-Chie Hung | Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
| US6399743B1 (en) | 1999-05-14 | 2002-06-04 | Dept. Of Veterans Affairs | Isolation and characterization of a rat epidermal growth factor related protein |
| US9486429B2 (en) | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
| US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| BR0013814A (pt) | 1999-08-27 | 2002-04-23 | Genentech Inc | Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2 |
| US20040086903A1 (en) * | 2000-12-29 | 2004-05-06 | Jean-Jacques Lareyre | Epididymal lipocalin gene and uses thereof |
| US20020169126A1 (en) * | 2001-03-21 | 2002-11-14 | Mien-Chie Hung | Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene |
| US20050069918A1 (en) | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
| US20100132058A1 (en) | 2004-07-23 | 2010-05-27 | Diatchenko Luda B | Methods and materials for determining pain sensitivity and predicting and treating related disorders |
| PT2247297T (pt) * | 2008-01-31 | 2019-04-24 | Univ Vanderbilt | Tratamento terapêutico para estados pulmonares |
| HUE045571T2 (hu) | 2008-01-31 | 2020-01-28 | Univ Vanderbilt | Koronáriás és artériás aneurizmás szubarachnoideális vérzés kezelésére szolgáló eljárások és készítmények |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| ES2067755T3 (es) * | 1989-06-22 | 1995-04-01 | Vestar Inc | Proceso de encapsulado. |
| ATE237694T1 (de) * | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
-
1991
- 1991-12-04 DK DK92902782.9T patent/DK0560932T3/da active
- 1991-12-04 AU AU91469/91A patent/AU651650B2/en not_active Ceased
- 1991-12-04 CA CA002096723A patent/CA2096723C/en not_active Expired - Fee Related
- 1991-12-04 JP JP4502955A patent/JPH06504671A/ja not_active Withdrawn
- 1991-12-04 WO PCT/US1991/009100 patent/WO1992010573A1/en not_active Ceased
- 1991-12-04 AT AT92902782T patent/ATE142261T1/de not_active IP Right Cessation
- 1991-12-04 ES ES92902782T patent/ES2093248T3/es not_active Expired - Lifetime
- 1991-12-04 EP EP92902782A patent/EP0560932B1/en not_active Expired - Lifetime
- 1991-12-04 US US08/070,410 patent/US5651964A/en not_active Expired - Fee Related
- 1991-12-04 DE DE69121903T patent/DE69121903T2/de not_active Expired - Fee Related
-
1996
- 1996-11-28 GR GR960403196T patent/GR3021805T3/el unknown
-
2001
- 2001-08-01 JP JP2001234289A patent/JP3323491B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69121903D1 (de) | 1996-10-10 |
| CA2096723C (en) | 2006-03-28 |
| EP0560932A1 (en) | 1993-09-22 |
| AU651650B2 (en) | 1994-07-28 |
| ATE142261T1 (de) | 1996-09-15 |
| DK0560932T3 (cg-RX-API-DMAC7.html) | 1997-02-17 |
| CA2096723A1 (en) | 1992-06-05 |
| JP2002114707A (ja) | 2002-04-16 |
| JP3323491B2 (ja) | 2002-09-09 |
| WO1992010573A1 (en) | 1992-06-25 |
| JPH06504671A (ja) | 1994-06-02 |
| AU9146991A (en) | 1992-07-08 |
| ES2093248T3 (es) | 1996-12-16 |
| US5651964A (en) | 1997-07-29 |
| DE69121903T2 (de) | 1997-04-10 |
| EP0560932B1 (en) | 1996-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0560932T3 (cg-RX-API-DMAC7.html) | ||
| WO1995016051A3 (en) | Methods and compositions for the suppression of neu mediated transformation | |
| Christl et al. | Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis | |
| Scheppach et al. | Role of short-chain fatty acids in the prevention of colorectal cancer | |
| Nishihira et al. | Molecular and cellular features of esophageal cancer cells | |
| Easty et al. | Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck | |
| Vielkind | Genetic control of cell differentiation in platyfish‐swordtail melanomas | |
| WO2002006526A8 (en) | Detection of copy number changes in colon cancer | |
| Russo et al. | Development pattern of human breast and susceptibility to carcinogenesis | |
| Tatematsu et al. | Independent induction of intestinal metaplasia and gastric cancer in rats treated with N-methyl-N′-nitro-N-nitrosoguanidine | |
| PL354334A1 (en) | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes | |
| Thalmann et al. | Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells | |
| Timmons et al. | Expression of galectin-7 during epithelial development coincides with the onset of stratification | |
| Easty et al. | Five human tumour cell lines derived from a primary squamous carcinoma of the tongue, two subsequent local recurrences and two nodal metastases | |
| Schmidt et al. | Gastrointestinal cancer studies in the human to nude mouse heterotransplant system | |
| Castle et al. | High level thrombospondin 1 expression in two NIH 3T3 cloned lines confers serum-and anchorage-independent growth. | |
| Blagosklonny | Cell immortality and hallmarks of cancer | |
| IL147123A0 (en) | Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies | |
| Russo et al. | Ape1/Ref-1 expression and cellular localization in human thyroid carcinoma cell lines | |
| Thijssen et al. | Local aromatase activity in human breast tissues | |
| Wang et al. | The in vitro effect of vitamin D3 analogue EB‐1089 on a human prostate cancer cell line (PC‐3) | |
| Nishi et al. | Stimulation of growth by both androgen and estrogen of the EMP-K1 transplantable tumor with androgen and estrogen receptors from human extramammary Paget's disease in nude mice | |
| Nio et al. | Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-β1 in invasive ductal carcinoma of the pancreas | |
| RU2000101293A (ru) | Производные бензо(5,6)циклогепта(1,2-в)пиридина для ингибирования фарнезил-протеин-трансферазы | |
| Marozzi et al. | by Transfection of H-2Kb Gene |